Drugs for the treatment of pulmonary arterial hypertension [ID12]

Pulmonary arterial hypertension (adults) - drugs: letter to stakeholders announcing removal of appraisal from the NICE work programme

Pulmonary arterial hypertension (adults) - drugs: provisional matrix for consultation on 28 Oct 08 

Pulmonary arterial hypertension (adults) - drugs: letter sent to new consultees and commentators on 28 Oct 08

Pulmonary arterial hypertension (adults) - drugs: draft remit and scope to consultees and commentators for consultation 28 Oct 08 

Pulmonary arterial hypertension (adults) - drugs: letter sent to existing consultees and commentators on 28 Oct 08

Pulmonary arterial hypertension (adults) - drugs: letter to consultees and commentators regarding delay to the appraisal

Pulmonary arterial hypertension (adults) - drugs: evaluation report

Additional report by the Assessment Group

Additional report by the Assessment Group (PDF 252 KB)

Additional report by the Assessment Group: further analyses

Additional report by the Assessment Group: further analyses (PDF 40 KB)

Results of the request for additional survival data and incremental results of cost-effectiveness analysis

Results of the request for additional survival data and incremental results of cost-effectiveness analysis (PDF 66 KB)

Overview

Overview (PDF 222 KB)

Response to consultee and commentator comments on the Assessment Report from the West Midlands Regional Health Technology Assessment Collaboration

Response to consultee and commentator comments on the Assessment Report from the West Midlands Regional Health Technology Assessment Collaboration (PDF 29 KB)

Assessment report

Assessment report (PDF 1.25 MB)

Results of the request for additional survival data and incremental results of cost-effectiveness analysis

Actelion Pharmaceuticals UK Ltd

Actelion Pharmaceuticals UK Ltd (PDF 12 KB)

Bayer Healthcare

Bayer Healthcare (PDF 12 KB)

Encysive Pharmaceuticals UK Ltd

Encysive Pharmaceuticals UK Ltd (PDF 12 KB)

NHS Quality Improvement Scotland

NHS Quality Improvement Scotland (PDF 13 KB)

Royal College of Physicians

Royal College of Physicians (PDF 13 KB)

National Pulmonary Vascular Diseases Unit 2

National Pulmonary Vascular Diseases Unit 2 (PDF 13 KB)

National Pulmonary Vascular Diseases Unit 1

National Pulmonary Vascular Diseases Unit 1 (PDF 13 KB)

Consultee and commentator comments on the assessment report

Actelion Pharmaceuticals UK Ltd

Actelion Pharmaceuticals UK Ltd (PDF 61 KB)

Bayer Healthcare

Bayer Healthcare (PDF 17 KB)

British Cardiovascular Society

British Cardiovascular Society (PDF 51 KB)

British Society for Rheumatology

British Society for Rheumatology (PDF 141 KB)

British Thoracic Society

British Thoracic Society (PDF 21 KB)

Department of Health

Department of Health (PDF 13 KB)

Encysive Pharmaceuticals UK Ltd

Encysive Pharmaceuticals UK Ltd (PDF 29 KB)

Pulmonary Arterial Hypertension Association UK

Pulmonary Arterial Hypertension Association UK (PDF 676 KB)

Royal College of Physicians

Royal College of Physicians (PDF 44 KB)

Royal College of Nursing

Royal College of Nursing (PDF 15 KB)

NHS Quality Improvement Scotland

NHS Quality Improvement Scotland (PDF 34 KB)

GlaxoSmithKline

GlaxoSmithKline (PDF 76 KB)

Non-manufacturer submission

Joint Submission by The West Midlands Specialised Commissioning Team(WMSCG), South Staffordshire Primary Care Trust, North West London Specialised Commissioning Team (London SCG)

Joint Submission by The West Midlands Specialised Commissioning Team(WMSCG), South Staffordshire Primary Care Trust, North West London Specialised Commissioning Team (London SCG) (PDF 24 KB)

Royal College of Physicians and British Cardiovascular Society

Royal College of Physicians and British Cardiovascular Society (PDF 412 KB)

Royal College of Nursing

Royal College of Nursing (PDF 15 KB)

Raynaud's & Scleroderma Association

Raynaud's & Scleroderma Association (PDF 35 KB)

Pulmonary Arterial Hypertension Association UK

Pulmonary Arterial Hypertension Association UK (PDF 676 KB)

British Society for Rheumatology

British Society for Rheumatology (PDF 100 KB)

Manufacturer submissions (executive summary only)

Schering Health Care Ltd

Schering Health Care Ltd (PDF 71 KB)

Pfizer Ltd

Pfizer Ltd (PDF 11 KB)

GlaxoSmithKline

GlaxoSmithKline (PDF 24 KB)

Encysive pharmaceuticals UK Ltd

Encysive pharmaceuticals UK Ltd (PDF 25 KB)

Actelion Pharmaceuticals UK Ltd

Actelion Pharmaceuticals UK Ltd (PDF 49 KB)

Expert written personal statements

Townsley

Townsley (PDF 24 KB)

Pannell

Pannell (PDF 21 KB)

Gin-Sing

Gin-Sing (PDF 15 KB)

Corris

Pulmonary arterial hypertension (adults) - drugs: treatment of pulmonary arterial hypertension letter

Pulmonary arterial hypertension (adults) - drugs: final protocol

Pulmonary arterial hypertension (adults) - drugs: final scope

Pulmonary arterial hypertension (adults) - drugs: comments on draft scope

Pulmonary arterial hypertension (adults) - drugs: comments on provisional matrix of consultees and commentators

Pulmonary arterial hypertension (adults) - drugs: additional analysis